Chargement de l’entreprise
Just reported
Q3 2026 results
From Waters's results release of 3 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
1,77B $US
+121 % y/y
+7,4 % q/qGuided
858,5M $US
midpoint
Above guide+106 %EPS, GAAP
Actual
0,82 $US
-67 % y/y
Guided
—
No guide given
Operating income, GAAP
Actual
128M $US
-33 % y/y
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue3,429B $US+8,3 % y/y Raised +1,8 %
- EPS, adjusted14,60 $US – 14,70 $USRaised +1,4 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Waters is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.259,4B $USA+
IDXXIdexx Laboratories Inc.55,5B $USA+
IQVIQVIA Holdings Inc.43,7B $USA
ILMNIllumina, Inc.31,3B $USA+
LHLabcorp Holdings Inc.30,1B $USA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Construit à partir des documents déposés par Waters Corporation auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.